A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington's Disease

Date Added
March 3rd, 2022
PRO Number
Pro00116394
Researcher
Federico Rodriguez-Porcel

List of Studies


Keywords
Movement Disorders
Summary

This study will test SAGE-718 to evaluate cognitive effects in subject with early manifest HD. The subject will be on study drug or placebo for 84 days. At clinic visits, participants will take the IP under staff supervision, followed
by assessments of cognitive function, health-related function and quality of life, and neuropsychiatric symptoms.

Institution
MUSC
Recruitment Contact
Sandra Wilson
843-792-4616
wilsosan@musc.edu



-- OR --